{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+vancomycin&page=2", "query": { "intervention": "IV vancomycin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+vancomycin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-13T20:51:08.702Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01570192", "title": "Clinical Trials to Reduce the Risk of Antimicrobial Resistance", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bacterial Pneumonia" ], "interventions": [ { "name": "IV meropenem", "type": "DRUG" }, { "name": "I.V. Meropenem", "type": "DRUG" }, { "name": "Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h", "type": "DRUG" }, { "name": "Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.", "type": "DRUG" }, { "name": "tobramycin nebulization", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2010-09", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2017-09-29", "last_synced_at": "2026-09-13T20:51:08.702Z", "location_count": 8, "location_summary": "San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "San Mateo", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "North Liberty", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01570192" }, { "nct_id": "NCT00077675", "title": "Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infections, Gram-positive Bacterial" ], "interventions": [ { "name": "Telavancin", "type": "DRUG" }, { "name": "vancomycin or antistaphylococcal penicillin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cumberland Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 201, "start_date": "2004-02", "completion_date": "2004-09", "has_results": true, "last_update_posted_date": "2019-01-16", "last_synced_at": "2026-09-13T20:51:08.702Z", "location_count": 1, "location_summary": "National City, California", "locations": [ { "city": "National City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077675" }, { "nct_id": "NCT06384651", "title": "Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Infections", "Ankle Arthritis" ], "interventions": [ { "name": "Intraosseous Vancomycin Injection", "type": "DRUG" }, { "name": "Intravenous Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-12-03", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-01-24", "last_synced_at": "2026-09-13T20:51:08.702Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06384651" }, { "nct_id": "NCT01196169", "title": "Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Staphylococcal Infections", "Methicillin-resistant Staphylococcus Aureus" ], "interventions": [ { "name": "Daptomycin", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mountain Home Research & Education Corporation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 28, "start_date": "2010-10", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2014-02-03", "last_synced_at": "2026-09-13T20:51:08.702Z", "location_count": 2, "location_summary": "Johnson City, Tennessee • Mountain Home, Tennessee", "locations": [ { "city": "Johnson City", "state": "Tennessee" }, { "city": "Mountain Home", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01196169" }, { "nct_id": "NCT04729322", "title": "Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Adenocarcinoma", "Metastatic Small Intestinal Adenocarcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Small Intestinal Adenocarcinoma AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Fecal Microbiota Transplantation", "type": "PROCEDURE" }, { "name": "Fecal Microbiota Transplantation Capsule", "type": "DRUG" }, { "name": "Metronidazole", "type": "DRUG" }, { "name": "Neomycin", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Vancomycin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2021-02-22", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-09-13T20:51:08.702Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04729322" }, { "nct_id": "NCT01764750", "title": "Dose Escalation Trial of Intrasite Vancomycin Pharmacokinetics", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Surgical Site Infection" ], "interventions": [ { "name": "Intrasite Vancomycin", "type": "DRUG" }, { "name": "IV Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2013-01", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2018-05-11", "last_synced_at": "2026-09-13T20:51:08.702Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01764750" }, { "nct_id": "NCT01252719", "title": "Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Wound Infection", "Abscess", "Systemic Inflammation", "Cellulitis" ], "interventions": [ { "name": "Single-Dose IV Oritavancin Diphosphate", "type": "DRUG" }, { "name": "IV Vancomycin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Melinta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 968, "start_date": "2010-12", "completion_date": "2012-11-30", "has_results": true, "last_update_posted_date": "2022-08-01", "last_synced_at": "2026-09-13T20:51:08.702Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01252719" }, { "nct_id": "NCT01104662", "title": "Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Complicated Skin and Skin Structure Infections", "S. Aureus Bacteremia", "Renal Impairment" ], "interventions": [ { "name": "Vancomycin", "type": "DRUG" }, { "name": "Daptomycin", "type": "DRUG" }, { "name": "Semi-Synthetic Penicillin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2010-04-19", "completion_date": "2012-06-12", "has_results": true, "last_update_posted_date": "2018-09-05", "last_synced_at": "2026-09-13T20:51:08.702Z", "location_count": 10, "location_summary": "Azusa, California • Los Angeles, California • Torrance, California + 7 more", "locations": [ { "city": "Azusa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01104662" }, { "nct_id": "NCT01401023", "title": "Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diarrhea", "Clostridium Difficile" ], "interventions": [ { "name": "Tigecycline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gary E. Stein, Pharm.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2011-07", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2018-07-10", "last_synced_at": "2026-09-13T20:51:08.702Z", "location_count": 2, "location_summary": "East Lansing, Michigan • Lansing, Michigan", "locations": [ { "city": "East Lansing", "state": "Michigan" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01401023" }, { "nct_id": "NCT00424190", "title": "Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bacterial Infections" ], "interventions": [ { "name": "IV Vancomycin plus IV Aztreonam", "type": "DRUG" }, { "name": "Ceftaroline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 698, "start_date": "2007-02", "completion_date": "2007-11", "has_results": true, "last_update_posted_date": "2017-03-14", "last_synced_at": "2026-09-13T20:51:08.702Z", "location_count": 15, "location_summary": "Dothan, Alabama • Long Beach, California • Los Angeles, California + 11 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00424190" } ] }